This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
lzheimer's disease (AD) is a chronic and neurodegenerative disease affecting the population over 65 years of age. This study
aimed to evaluate the therapeutic role of mesenchymal stem cells (MSCs) against AD in rats. The MSCs were harvested
from bone marrow of femoral bones of male rats, grown and propagated in culture then characterized morphologically and
by the detection of CD14, CD29, CD34, CD44, CD45 and CD106 genes expression. Fifty female rats were classified into 5
groups. Group (1): was control. Groups from (2) to (5) were orally administered with aluminum chloride for induction of AD.
Group (2): was left untreated; groups (3) and (4): were treated orally with rivastigmine and intraperitoneally with cerebrolysin
respectively and group (5): was infused with a single dose of BM-MSCs intravenously. Y-chromosome gene was assessed in
the brain tissue of the female rats. Brain seladin-1 and nestin genes expression were detected by RT-PCR. While, brain ChAT
and survivin expressions were determined by immunohistochemistry. Histopathological investigation of brain tissues was done.
The AD group showed significant decrease in the number of positive cells for ChAT and survivin expressions while, treatment
with rivastigmine, cerebrolysin or BM-MSCs produced significant increase in the number of positive cells for them. Also, AD
group showed significant decrease in brain nestin and seladin-1 genes expression while, the groups treated with rivastigmine,
cerebrolysin or BM-MSCs showed significant increase in their expressions. Brain sections of AD rats showed acellular plaques in
the hippocampus. While, all treated groups showed intact histological structure of the hippocampus. These improvements might
be attributed to the anti-apoptotic and neurotrophic efficacy of BM-MSCs.
Hanaa Hamdy Ahmed has completed her Ph.D. at the age of 35 years from Faculty of Science, Cairo University and postdoctoral studies from
National Research Centre, Medical Research Division. She has been a Head of Hormones Department at the National Research
Centre since 2012
uptil now. She has published more than 110 papers in the field of Medical Research in reputed journals. She won a Scientific Encouraging award in
Medical Sciences in 2006. She is serving as an Editorial Board Member and as a reviewer board member in more than 30 International Journals
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals